GBA1-Associated Parkinson's Disease Is a Distinct Entity

Area of Science:

• Neuroscience
• Genetics
• Pathology

Background:

• GBA1-associated Parkinson's disease (GBA1-PD) is increasingly recognized as a distinct parkinsonian disorder.
• It differs from idiopathic Parkinson's disease (iPD) in clinical presentation, progression, and underlying genetic factors.

Purpose of the Study:

• To review the unique pathophysiological features, clinical progression, and genetic underpinnings of GBA1-PD.
• To differentiate GBA1-PD from iPD and explore therapeutic implications.

Main Methods:

• Review of existing literature on GBA1-PD.
• Analysis of genetic mutations in the GBA1 gene and their impact on beta-glucocerebrosidase (GCase) function.
• Synthesis of clinical, pathological, and molecular data.

Main Results:

• GBA1-PD typically shows earlier onset, faster progression, and poorer response to standard treatments compared to iPD.
• Cognitive impairment and non-motor symptoms are more pronounced in GBA1-PD.
• Mutations in GBA1 lead to GCase deficiency via haploinsufficiency or gain-of-function mechanisms, promoting alpha-synuclein aggregation.

Conclusions:

• GBA1-PD represents a distinct clinical and pathobiological phenotype requiring specific management.
• The 'gain of function' mechanism is considered the most plausible driver of GBA1-PD pathogenesis.
• Targeted therapies, particularly small molecular chaperones, show promise for GBA1-PD treatment.